SkinCure_Logo_600px (002).png
SkinCure Oncology’s GentleCure™ Experience to be Featured in National Public Health PSA Series
08 mai 2024 09h00 HE | SkinCure Oncology LLC
GentleCure will be recognized as an innovative healthcare technology in an upcoming public service announcement (PSA) about nonmelanoma skin cancer.
journeylogo (1).jpg
Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
07 mai 2024 08h30 HE | Journey Medical Corporation
SCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the...
Moonlake logo.png
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
07 mai 2024 08h00 HE | MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...
Pacific Software Inc. Announces a Landmark Asset Acquisition from Dreamaderm Inc.
06 mai 2024 08h00 HE | Pacific Software Inc.
Pacific Software acquires Dreamaderm assets, including Dermatrix, a peptide-enhancing cosmeceutical for diverse dermatological applications.
22157.jpg
Dermatology Collaboration and Licensing Deals Report, 2016 to 2024, Featuring 600+ Companies and 400+ Deals
02 mai 2024 07h33 HE | Research and Markets
Dublin, May 02, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Dermatology Collaboration and...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
02 mai 2024 07h00 HE | Kymera Therapeutics, Inc.
KT-474/SAR444656 (IRAK4) Phase 2 clinical trials ongoing in HS and AD with data expected in the first half of 2025 KT-621 (STAT6) expected to start Phase 1 in the second half of 2024 and KT-294...
journeylogo (1).jpg
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
01 mai 2024 16h01 HE | Journey Medical Corporation
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses...
Kamari Pharma Appoints Dr. John Doux to its Board of Directors
30 avr. 2024 09h00 HE | Kamari Pharma
NESS ZIONA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic...
European Scar Management Market
Europe Scar Management Market Analysis Report 2024: A $350+ Million Market by 2030 with Advancis Medical, Bayer, B. Braun, Molnlycke Health Care, Smith & Nephew, and Stratpharma Dominating
29 avr. 2024 10h07 HE | Research and Markets
Dublin, April 29, 2024 (GLOBE NEWSWIRE) -- The "Europe Scar Management Market: Analysis and Forecast, 2023-2030" report has been added to ResearchAndMarkets.com's offering. The Europe scar...
journeylogo (1).jpg
Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024
25 avr. 2024 08h30 HE | Journey Medical Corporation
SCOTTSDALE, Ariz., April 25, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...